US affiliate of Merz Pharma, Merz has acquired Cuvposa (glycopyrrolate) oral solution, the only FDA approved treatment for pediatric chronic severe drooling (sialorrhea) associated with neurologic conditions such as cerebral palsy.
Cuvposa is an inhibitor of acetylcholine receptors located on certain peripheral tissues such as salivary glands, which cause reduction in the rate of salivation.
Cerebral palsy (CP) is a lifelong condition, which includes a group of non-progressive, neurological disorders affecting body movement and muscle coordination.
Merz Pharmaceuticals senior neurology medical expert Kapil Sethi said the FDA has classified Cuvposa as an orphan drug since sialorrhea is a rare disorder in pediatric patients with neurologic conditions.
"Due to the limited treatment options available, sialorrhea is an all-too-often poorly managed condition in pediatric patients suffering from neurologic disorders such as cerebral palsy," Sethi added.
Merz president and chief executive officer Bill Humphries said, "The acquisition of CUVPOSA® is a promising addition to our neurology business and reflects our commitment to becoming a recognized leader in the treatment of movement disorders and related conditions in the U.S."
FDA approved Cuvposa in July 2010 and the product has been commercially available in the US since April 2011.